We are live on ! Find out more
FFTY icon

CapForce IBD 50 ETF

50 hedge funds and large institutions have $25.7M invested in CapForce IBD 50 ETF in 2022 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 12 increasing their positions, 19 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.62% less ownership

Funds ownership: 26.51%25.89% (-0.62%)

14% less funds holding

Funds holding: 5850 (-8)

16% less capital invested

Capital invested by funds: $30.7M → $25.7M (-$4.99M)

37% less repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 19

75% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 8

Holders
50
Holders Change
-8
Holders Change %
-13.79%
% of All Funds
0.86%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
2
Increased
12
Reduced
19
Closed
8
Calls
Puts
Net Calls
Net Calls Change

FFTY Hedge Fund Activity: Q3 2022 in Review

50 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in CapForce IBD 50 ETF (FFTY) for Q3 2022, worth a combined $25.7M — down 16% from $30.7M a quarter earlier.

Sellers outnumbered buyers: 8 funds closed out of FFTY and 2 opened new positions — a net loss of 6 holders — while 19 trimmed existing stakes and 12 added.

The largest buyer was Royal Bank of Canada, adding an estimated $1.16M. The largest seller was Raymond James & Associates, cutting an estimated $914K.

  • 50 institutional investors held CapForce IBD 50 ETF (FFTY) as of Q3 2022, down from 58 in Q2 2022.
  • Funds reported $25.7M of CapForce IBD 50 ETF stock for Q3 2022, down 16% quarter-over-quarter.
  • 2 funds opened new CapForce IBD 50 ETF positions in Q3 2022 and 8 closed out, a net change of -6 holders.
  • The largest CapForce IBD 50 ETF buyer in Q3 2022 was Royal Bank of Canada, an estimated $1.16M added.
  • The largest CapForce IBD 50 ETF seller in Q3 2022 was Raymond James & Associates, an estimated $914K sold.

Based on aggregated 13F filings for Q3 2022.